GlaxoSmithKline PLC Insider Profile

32 Followers
GlaxoSmithKline PLC, Ten Percent Owner at Innoviva, holds 16.78M shares in Wave Life Sciences (Ticker: WVE), holds 0.00 shares in Theravance Biopharma (Ticker: TBPH), holds 1.01M shares in CVRx (Ticker: CVRX). Most recently, GlaxoSmithKline PLC Bought ― shares of Wave Life Sciences on Oct 01, 2024 for an estimated value of 22.34M.
tipranks
GlaxoSmithKline PLC

GlaxoSmithKline PLC
Innoviva (INVA)
Ten Percent Owner

Ranked #6,825 out of 99,335 Corporate Insiders

Profitable Transactions

45%
17 out of 38 Profitable Transactions

Average Return

+10.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$508M
54.31%
20.96%
9.15%
7.21%
8.38% Others
A breakdown of GlaxoSmithKline PLC's holdings

Insider Roles

Wave Life Sciences
(WVE)
Ten Percent Owner
Progyny
(PGNY)
Ten Percent Owner
Bicycle Therapeutics
(BCYC)
Ten Percent Owner
Lyell Immunopharma
(LYEL)
Ten Percent Owner
+12 other positions
Roles that GlaxoSmithKline PLC holds in companies

Most Profitable Insider Trade

Stock:
Wave Life Sciences
(WVE)
Rating:Informative Buy
Date:Jan 30, 2024 - Today
Return:+281.40%
The most profitable trade made by GlaxoSmithKline PLC

GlaxoSmithKline PLC's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Innoviva
May 24, 2021
Ten Percent Owner
Informative Sell
392.06M
$0.00
Spero Therapeutics
Jul 17, 2018
Ten Percent Owner
Informative Buy
1.00M
$2.57M
Liquidia Technologies
Aug 01, 2018
Former 10% holder
Informative Buy
1.64M
$6.70M
PRNB
Principia Biopharma
Oct 22, 2019
Informative Buy
10.00M
$298.43M
TPTX
Turning Point Therapeutics
May 26, 2020
Informative Buy
5.00M
$171.30M
Fulcrum Therapeutics
Jul 24, 2019
Ten Percent Owner
Uninformative Buy
$6.50M
Progyny
May 21, 2020
Ten Percent Owner
Informative Sell
103.00M
$106.42M
Bicycle Therapeutics
Sep 18, 2020
Ten Percent Owner
Informative Sell
91.81K
$46.46M
Nkarta
Jul 16, 2020
Director, Ten Percent Owner
Informative Buy
15.00M
$10.68M
PAND
Pandion Therapeutics
Jul 22, 2020
Uninformative Buy
$135.01M
DBTX
Decibel Therapeutics
Feb 19, 2021
Uninformative Buy
$5.81M
Lyell Immunopharma
Jun 23, 2021
Ten Percent Owner
Uninformative Buy
$36.61M
CVRx
Jul 06, 2021
Ten Percent Owner
Uninformative Buy
$15.95M
Wave Life Sciences
Oct 01, 2024
Ten Percent Owner
Informative Buy
22.34M
$275.79M
Theravance Biopharma
Sep 20, 2022
Former 10% Owner
Uninformative Sell
94.04M
$0.00
AGTC
Applied Genetic Technologies
Feb 24, 2015
Informative Sell
11.07M
$564.52K
HTG Molecular Diagnostics
Mar 29, 2017
Ten Percent Owner
Informative Sell
3.04M
$12.59K
~ANAC
Anacor Pharmaceuticals
Nov 24, 2010
Informative Buy
5.00M
$450.10M
CCXI
ChemoCentryx
Oct 18, 2018
Informative Sell
85.85M
$0.00
OMED
OncoMed Pharma
Jul 23, 2013
Uninformative Buy
$2.32M
CNCE
Concert Pharma
Feb 20, 2014
Informative Buy
490.00K
$11.35M
Genocea Biosciences
Jul 30, 2020
Ten Percent Owner
Informative Buy
2.84M
$69.40K
Response Genetics
Sep 21, 2012
Ten Percent Owner
Informative Buy
$70.00K
Amicus
Oct 28, 2014
Former 10% Owner (1)
Informative Sell
59.86M
$0.00
MAXY
Maxygen
Jan 04, 2010
Informative Sell
27.14M
~PATH
Nupathe Inc
Feb 24, 2014
Uninformative Sell
Quest Diagnostics
Feb 02, 2011
Director, Ten Percent Owner
Informative Sell
1.69B
$0.00
List of latest transactions for each holding click on a transaction to see GlaxoSmithKline PLC's performance on stock

GlaxoSmithKline PLC insider profile FAQ

What is the percentage of profitable transactions made by GlaxoSmithKline PLC?
The percentage of profitable transactions made by GlaxoSmithKline PLC is 45%.
    What is the average return per transaction made by GlaxoSmithKline PLC?
    The average return per transaction made by GlaxoSmithKline PLC is 10.60%.
      What stocks does GlaxoSmithKline PLC hold?
      GlaxoSmithKline PLC holds: INVA, SPRO, LQDA, PRNB, TPTX, FULC, PGNY, BCYC, NKTX, PAND, DBTX, LYEL, CVRX, WVE, TBPH, AGTC, HTGMQ, ~ANAC, CCXI, OMED, CNCE, GNCAQ, RGDXQ, FOLD, MAXY, ~PATH, DGX stocks.
        What was GlaxoSmithKline PLC’s latest transaction?
        GlaxoSmithKline PLC latest transaction was an Informative Buy of $22.34M.
          What was GlaxoSmithKline PLC's most profitable transaction?
          GlaxoSmithKline PLC’s most profitable transaction was an Informative Buy of WVE stock on January 30, 2024. The return on the trade was 281.40%.
            What is GlaxoSmithKline PLC's role in Innoviva?
            GlaxoSmithKline PLC's role in Innoviva is Ten Percent Owner.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.